Brief: Biontech And Ryvu Therapeutics To Develop And Commercialize Immuno-Modulatory Small Molecule Candidates

Ryvu Therapeutics SA

30/11/2022 06:06

Nov 30 (Reuters) - Biontech Se  22UAy.DE :
    * BIONTECH AND RYVU THERAPEUTICS ENTER INTO GLOBAL
COLLABORATION
TO DEVELOP AND COMMERCIALIZE IMMUNO-MODULATORY SMALL MOLECULE
CANDIDATES
    * COMPANIES ENTER A MULTI-TARGET RESEARCH COLLABORATION TO
DEVELOP
MULTIPLE SMALL MOLECULE PROGRAMS TARGETING IMMUNE MODULATION IN
CANCER AND POTENTIALLY OTHER DISEASE AREAS BASED ON TARGETS
SELECTED BY BIONTECH
    * IN ADDITION TO THESE PROGRAMS, BIONTECH WILL RECEIVE A
GLOBAL,
EXCLUSIVE LICENSE TO DEVELOP AND COMMERCIALIZE RYVU'S STING
AGONIST PORTFOLIO AS STANDALONE SMALL MOLECULES
    * RYVU WILL RECEIVE EUR 40 MILLION FROM BIONTECH, COMPRISED
OF A
EUR 20 MILLION UPFRONT PAYMENT AND AN EQUITY INVESTMENT OF EUR
20 MILLION, AS WELL AS RESEARCH FUNDING
    * ADDITIONALLY, RYVU IS ELIGIBLE TO RECEIVE RESEARCH AND
DEVELOPMENT AND COMMERCIAL MILESTONE PAYMENTS IN ADDITION TO LOW
SINGLE-DIGIT ROYALTIES

Further company coverage:  22UAy.DE 
 (Reporting by Berlin Newsroom)
 ((berlin.newsroom@thomsonreuters.com;))